Standard BioTools agrees to sell Microfluidics business to ARCHIMED

• Standard BioTools agreed to sell its Microfluidics business to healthcare-focused investor ARCHIMED.
• Closing targeted in about 30 days, subject to customary closing conditions.
• Microfluidics operations remain within Standard BioTools until the deal closes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Standard BioTools Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610051605PRIMZONEFULLFEED9839881) on October 05, 2026, and is solely responsible for the information contained therein.